Ilyas, S, Moncrieff, J.
Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. Br J Psychiatry
2012; 200(5): 393–8.
Royal College of Psychiatrists. Antidepressants. Royal College of Psychiatrists, 2009.
Smith, A, Traganza, E, Harrison, G.
Studies on the effectiveness of antidepressant drugs. Psychopharmacol Bull
1969; Suppl: 1–53.
Khin, NA, Chen, YF, Yang, Y, Yang, P, Laughren, TP.
Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry
2011; 72(4): 464–72.
Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Johnson, BT.
Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med
2008; 5(2): e45.
Turner, EH, Matthews, AM, Linardatos, E, Tell, RA, Rosenthal, R.
Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med
2008; 358(3): 252–60.
Leucht, S, Fennema, H, Engel, R, Kaspers-Janssen, M, Lepping, P, Szegedi, A.
What does the HAMD mean?
J Affect Disord
2013; 148(2–3): 243–8.
Moncrieff, J, Kirsch, I.
Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences. Contemp Clin Trials
2015; 43: 60–2.
Fournier, JC, DeRubeis, RJ, Hollon, SD, Dimidjian, S, Amsterdam, JD, Shelton, RC, et al.
Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA
2010; 303(1): 47–53.
Gibbons, RD, Hur, K, Brown, CH, Davis, JM, Mann, JJ.
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry
2012; 69(6): 572–9.
Walsh, BT, Seidman, SN, Sysko, R, Gould, M.
Placebo response in studies of major depression: variable, substantial, and growing. JAMA
2002; 287(14): 1840–7.
Medical Research Council. Clinical trial of the treatment of depressive illness. Br Med J
1965; 1: 881–6.
Zhang, Y, Yang, H, Yang, S, Liang, W, Dai, P, Wang, C, et al.
Antidepressants for bipolar disorder: a meta-analysis of randomized, double-blind, controlled trials. Neural Regen Res
2013; 8(31): 2962–74.
Moncrieff, J, Cohen, D.
Rethinking models of psychotropic drug action. Psychother Psychosom
2005; 74(3): 145–53.
Moncrieff, J, Cohen, D.
Do antidepressants cure or create abnormal brain states?
2006; 3(7): e240.
Lacasse, JR, Leo, J.
Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med
2005; 2(12): e392.
Dumont, GJ, de Visser, SJ, Cohen, AF, van Gerven, JM.
Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br J Clin Pharmacol
2005; 59(5): 495–510.
Goldsmith, L, Moncrieff, J.
The psychoactive effects of antidepressants and their association with suicidality. Curr Drug Saf
2011; 6(2): 115–21.
Sharma, T, Guski, LS, Freund, N, Gotzsche, PC.
Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ
2016; 352: i65.
Reefhuis, J, Devine, O, Friedman, JM, Louik, C, Honein, MA.
Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ
2015; 351: h3190.
Fava, GA, Gatti, A, Belaise, C, Guidi, J, Offidani, E.
Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom
2015; 84(2): 72–81.
Farnsworth, KD, Dinsmore, WW.
Persistent sexual dysfunction in genitourinary medicine clinic attendees induced by selective serotonin reuptake inhibitors. Int J STD AIDS
2009; 20(1): 68–9.